CN111643673B - 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用 - Google Patents

一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用 Download PDF

Info

Publication number
CN111643673B
CN111643673B CN202010653123.0A CN202010653123A CN111643673B CN 111643673 B CN111643673 B CN 111643673B CN 202010653123 A CN202010653123 A CN 202010653123A CN 111643673 B CN111643673 B CN 111643673B
Authority
CN
China
Prior art keywords
nano
drug
protein
tumor
zif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010653123.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111643673A (zh
Inventor
张晓龙
曾永毅
刘小龙
丁磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mengchao Hepatobiliary Hospital Of Fujian Medical University (fuzhou Hospital For Infectious Diseases)
Original Assignee
Mengchao Hepatobiliary Hospital Of Fujian Medical University (fuzhou Hospital For Infectious Diseases)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mengchao Hepatobiliary Hospital Of Fujian Medical University (fuzhou Hospital For Infectious Diseases) filed Critical Mengchao Hepatobiliary Hospital Of Fujian Medical University (fuzhou Hospital For Infectious Diseases)
Priority to CN202010653123.0A priority Critical patent/CN111643673B/zh
Priority to PCT/CN2020/112583 priority patent/WO2022007153A1/fr
Publication of CN111643673A publication Critical patent/CN111643673A/zh
Application granted granted Critical
Publication of CN111643673B publication Critical patent/CN111643673B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202010653123.0A 2020-07-08 2020-07-08 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用 Active CN111643673B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010653123.0A CN111643673B (zh) 2020-07-08 2020-07-08 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用
PCT/CN2020/112583 WO2022007153A1 (fr) 2020-07-08 2020-08-31 Nanomédicament ciblant une tumeur renfermant simultanément un photosensibilisateur et une protéine, et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010653123.0A CN111643673B (zh) 2020-07-08 2020-07-08 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用

Publications (2)

Publication Number Publication Date
CN111643673A CN111643673A (zh) 2020-09-11
CN111643673B true CN111643673B (zh) 2022-09-13

Family

ID=72342028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010653123.0A Active CN111643673B (zh) 2020-07-08 2020-07-08 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用

Country Status (2)

Country Link
CN (1) CN111643673B (fr)
WO (1) WO2022007153A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018455A (zh) * 2021-03-16 2021-06-25 北京电子科技职业学院 一种透明质酸修饰的负载疏水药物的纳米载体及其制备方法和应用
CN113384696A (zh) * 2021-06-07 2021-09-14 深圳大学 一种纳米光敏剂、制备方法及其应用
CN113372904B (zh) * 2021-06-08 2022-08-23 青岛科技大学 一种用于肿瘤成像和靶向协同治疗的谷胱甘肽响应纳米探针及其构建方法
CN113384709B (zh) * 2021-06-28 2022-03-11 西南大学 一种葡聚糖-原卟啉前药纳米胶束的制备和应用
CN113651872A (zh) * 2021-08-09 2021-11-16 大连理工大学 一类基于两亲性多肽的自组装纳米光敏剂及其制备方法与应用
CN113952470B (zh) * 2021-08-31 2023-08-29 中国科学院长春应用化学研究所 一种双重活性氧产生器的纳米颗粒及其制备方法、应用
CN114099706A (zh) * 2021-11-30 2022-03-01 江南大学 一种用于乳腺癌治疗的mof药物载体及其制备方法
CN114129738A (zh) * 2021-11-30 2022-03-04 广东省人民医院 一种肿瘤微环境响应的免疫治疗抗体复合材料及制备抗肿瘤药物的用途
CN114432458A (zh) * 2022-01-21 2022-05-06 同济大学 一种细菌载药系统及其制备方法
CN114601925B (zh) * 2022-01-27 2023-10-17 西安交通大学医学院第一附属医院 透明质酸与rsl3共同修饰的光敏纳米材料、制备方法及其应用
CN114887077A (zh) * 2022-02-15 2022-08-12 浙江大学 一种具有线粒体靶向能力的有机金属纳米材料的制备方法
CN114437183A (zh) * 2022-02-17 2022-05-06 中国农业科学院兰州兽医研究所 一种基于金属有机框架仿生矿化提高病毒样颗粒热稳定性的方法
CN114699537A (zh) * 2022-03-07 2022-07-05 西安交通大学医学院第一附属医院 一种改善缺氧增敏pd-1抗体疗效的ros响应抗癌药物
CN114668712B (zh) * 2022-03-24 2023-09-26 深圳大学 一种缓释微针贴片及其制备方法
CN114657098A (zh) * 2022-03-28 2022-06-24 深圳大学 一种经修饰的微生物及其修饰方法和应用、抗肿瘤药物
CN114796156B (zh) * 2022-04-18 2023-11-21 河北医科大学 一种线粒体靶向的光热/化疗协同的纳米药物递送粒子及其制备方法和应用
CN114848813A (zh) * 2022-04-18 2022-08-05 湖北工业大学 一种自供应h2o2/o2和消耗gsh的金属有机框架包覆纳米颗粒及其制备方法与应用
CN115025238B (zh) * 2022-05-19 2024-03-19 北京柏欧利诺生物科技有限公司 一种尺寸可控的线粒体靶向型光敏性纳米颗粒及其制备方法
CN115227828B (zh) * 2022-06-23 2024-02-27 中国药科大学 一种基于四氧化三铁的磁靶向蛋白递送纳米组装体的制备方法及应用
CN114984303B (zh) * 2022-07-01 2023-08-29 西南交通大学 一种可原位产氧的喷雾式水凝胶敷料、制备方法及应用
CN116004591B (zh) * 2022-07-13 2024-04-05 吉林大学 一种近红外驱动嗜热酶催化型抗肿瘤靶向纳米制剂
CN115531536B (zh) * 2022-08-16 2023-09-22 南京师范大学 一种具有高单线态氧效率的近红外bodipy@zif-8纳米光敏剂的制备方法和应用
CN115385861B (zh) * 2022-08-30 2024-03-29 内蒙古大学 一种荧光探针及其制备方法和应用
CN115137845B (zh) * 2022-08-30 2022-11-01 潍坊医学院附属医院 一种含动态亚胺键的金属有机框架共价同时固载阿霉素和卟啉复合物及其制备方法和应用
CN115737932B (zh) * 2022-11-23 2024-04-26 国纳之星(上海)纳米科技发展有限公司 负载x射线诱导光动力治疗/放疗协同诊疗一体化探针的骨水泥的制备及产品和应用
CN116271084A (zh) * 2023-01-04 2023-06-23 深圳市第二人民医院 一种基于趋磁细菌的药物磁递送系统及其制备方法和应用
CN116077657A (zh) * 2023-02-28 2023-05-09 中国科学院长春应用化学研究所 一种用于调节肿瘤微环境的活性氧纳米材料及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120090317A (ko) * 2011-02-07 2012-08-17 고려대학교 산학협력단 미생물 광사멸입자 및 미생물 광사멸방법
CN110200943A (zh) * 2019-07-05 2019-09-06 北京化工大学 一种聚氨基酸配位纳米粒子及其制备方法和作为在声动力肿瘤治疗的药物的应用
CN110731961A (zh) * 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
CN110898223A (zh) * 2019-12-13 2020-03-24 江南大学 一种基于糖基金属框架材料的肝靶向治疗药物及制备方法
CN111265533A (zh) * 2019-11-25 2020-06-12 上海纳米技术及应用国家工程研究中心有限公司 一种基于脂质膜和金属有机框架的核壳纳米颗粒的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106362146B (zh) * 2016-08-10 2019-04-05 福州大学 一种zif-8@酞菁锌复合材料的制备及其应用
CN109529036A (zh) * 2018-12-21 2019-03-29 上海纳米技术及应用国家工程研究中心有限公司 基于金属有机框架ZIF-8的pH敏感和光热治疗探针的制备方法
CN110522910B (zh) * 2019-08-01 2020-11-06 山东大学 基于金属有机框架纳米给药系统及其制备方法和应用
CN110693883A (zh) * 2019-11-21 2020-01-17 安徽医科大学第一附属医院 包载雷帕霉素的锌有机框架载药系统的制备方法及其应用
CN111320760B (zh) * 2020-02-28 2022-11-25 南开大学 一种多孔框架材料、包含该材料的酶制剂及制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120090317A (ko) * 2011-02-07 2012-08-17 고려대학교 산학협력단 미생물 광사멸입자 및 미생물 광사멸방법
CN110731961A (zh) * 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
CN110200943A (zh) * 2019-07-05 2019-09-06 北京化工大学 一种聚氨基酸配位纳米粒子及其制备方法和作为在声动力肿瘤治疗的药物的应用
CN111265533A (zh) * 2019-11-25 2020-06-12 上海纳米技术及应用国家工程研究中心有限公司 一种基于脂质膜和金属有机框架的核壳纳米颗粒的制备方法
CN110898223A (zh) * 2019-12-13 2020-03-24 江南大学 一种基于糖基金属框架材料的肝靶向治疗药物及制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A natural polysaccharide mediated MOF-based Ce6 delivery system with improved biological properties for photodynamic therapy;Xinwei Fu，et al.;《Journal of Materials Chemistry B》;20200130;第8卷(第7期);第1481-1488页 *
An O2 Self-Sufficient Biomimetic Nanoplatform for Highly Specific and Efficient Photodynamic Therapy;Hong Cheng，et al.;《 Advanced Functional Materials》;20160920;第26卷(第43期);第7847-7860页 *
Inner mechanism of protection of mitochondrial electron-transfer proteins against oxidative damage. Focus on hydrogen peroxide decomposition;Erik Sedlak，et al.;《Biochimie》;20170914;第142卷;第152-157页 *

Also Published As

Publication number Publication date
CN111643673A (zh) 2020-09-11
WO2022007153A1 (fr) 2022-01-13

Similar Documents

Publication Publication Date Title
CN111643673B (zh) 一种同时包载光敏剂和蛋白质的肿瘤靶向纳米药物及其应用
CN108653288B (zh) 一种乏氧响应聚合物纳米粒及其应用
Liang et al. A novel Pt–TiO2 heterostructure with oxygen‐deficient layer as bilaterally enhanced sonosensitizer for synergistic chemo‐sonodynamic cancer therapy
Wang et al. Upconverted metal–organic framework janus architecture for near-infrared and ultrasound co-enhanced high performance tumor therapy
Wei et al. Photo‐Reduction with NIR Light of Nucleus‐Targeting PtIV Nanoparticles for Combined Tumor‐Targeted Chemotherapy and Photodynamic Immunotherapy
Lu et al. Nanoscale metal–organic frameworks for therapeutic, imaging, and sensing applications
Wang et al. Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy
Wang et al. A nanostructured phthalocyanine/albumin supramolecular assembly for fluorescence turn-on imaging and photodynamic immunotherapy
Yang et al. Construction of pH/glutathione responsive chitosan nanoparticles by a self-assembly/self-crosslinking method for photodynamic therapy
CN113751079B (zh) 一种生物材料负载的钙钛矿-二氧化钛纳米复合光催化剂及其构建方法和应用
Xia et al. Enhanced photodynamic therapy through supramolecular photosensitizers with an adamantyl-functionalized porphyrin and a cyclodextrin dimer
Gomes et al. Photobiological and ultrastructural studies of nanoparticles of poly (lactic-co-glycolic acid)-containing bacteriochlorophyll-a as a photosensitizer useful for PDT treatment
CN105999283A (zh) 一种负载阿霉素的聚乙烯亚胺-透明质酸修饰的锂皂石包裹金纳米颗粒的制备方法
Zhu et al. Facile preparation of indocyanine green and tiny gold nanoclusters co-loaded nanocapsules for targeted synergistic sono-/photo-therapy
Zheng et al. Photoactivatable nanogenerators of reactive species for cancer therapy
Yu et al. A robust Au@ Cu2-xS nanoreactor assembled by silk fibroin for enhanced intratumoral glucose depletion and redox dyshomeostasis
Liu et al. X-ray-triggered CO release based on GdW10/MnBr (CO) 5 nanomicelles for synergistic radiotherapy and gas therapy
Wu et al. Near-infrared light-initiated upconversion nanoplatform with tumor microenvironment responsiveness for improved photodynamic therapy
Chen et al. Mitochondria-targeting upconversion nanoparticles@ MOF for multiple-enhanced photodynamic therapy in hypoxic tumor
Zheng et al. Fabrication of denatured BSA-hemin-IR780 (dBHI) nanoplatform for synergistic combination of phototherapy and chemodynamic therapy
Li et al. Water-soluble porphyrin-based nanoparticles derived from electrostatic interaction for enhanced photodynamic therapy
Lin et al. A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni-or multi-modal dynamic treatment for oncotherapy
CN110354276B (zh) 一种前药及其制备方法和应用
Sun et al. Pt/Ag‐PEG‐Ce6 Nanosystem with Enhanced Near‐Infrared Absorption and Peroxidase‐Like Activity for Synergistic Photodynamic/Photothermal Therapy
CN112057618A (zh) 一种Fe(III)-ART纳米粒子、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant